Agammaglobulinemia
MONDO:0015977A decreased level of serum immunoglobulins. It may be inherited or acquired. It is caused by decreased or inefficient production of immunoglobulins from B cells or by a decrease in the numbers of B cells themselves. Low levels of immunoglobulins will affect the immune system's ability to combat bacterial infection. Supplementation of immunoglobulins is needed to prevent worsening outcomes.
Also known as: agammaglobulinemia, Gammaglobulin Deficiency, Immunoglobulin Deficiency, antibody Deficiency
85 clinical trials for this condition and its sub-types, 16 tagged with Agammaglobulinemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Agammaglobulinemia
-
Syndromic agammaglobulinemia 7 trials · 37 incl. sub-types
3 sub-types
- Common variable immunodeficiency 29 trials · 31 incl. sub-types Sub-types →
- Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome 0 trials
- Transient hypogammaglobulinemia 0 trials Sub-types →
-
Activated PI3K-delta syndrome 5 trials · 6 incl. sub-types
2 sub-types
- Immunodeficiency 14 6 trials
- Immunodeficiency 36 with lymphoproliferation 0 trials
-
Isolated agammaglobulinemia 0 trials · 4 incl. sub-types
2 sub-types
- Bruton-type agammaglobulinemia 4 trials
- Autosomal agammaglobulinemia 1 trial Sub-types →
-
Good syndrome 0 trials
-
Congenital agammaglobulinemia 0 trials
-
Immunodeficiency 61 0 trials
Most studied deeper sub-types
-
New hope for cancer survivors: drug aims to shield against Life-Threatening infections
Disease control Recruiting nowThis study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Can a simple antibody infusion shield myeloma patients from infections?
Disease control Recruiting nowThis study tests whether IgPro20 (HIZENTRA), a concentrated antibody solution given under the skin, can prevent infections in people with multiple myeloma who have low antibody levels due to bispecific antibody therapy. About 100 participants will either receive IgPro20 plus stan…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug aims to shield autoimmune patients from Life-Threatening infections
Disease control Recruiting nowThis study tests whether a medicine called Panzyga can prevent major infections in people with autoimmune or rheumatic conditions who have low antibody levels after receiving B-cell depletion therapy. About 360 adults will receive either Panzyga or a placebo, and researchers will…
Phase 3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for blood cancer patients: drug aims to slash infection risk
Disease control Recruiting nowThis study tests whether a medicine called XEMBIFY, given every two weeks alongside standard care, can reduce serious bacterial infections in adults with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) who also have low antibody lev…
Phase 3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New IVIG therapy V-IMMUNE tested in phase III trial for immune deficiency
Disease control Recruiting nowThis phase III trial tests V-IMMUNE, an intravenous immunoglobulin (IVIG) product, in about 50 people with primary immunodeficiency (PID). Participants, aged 2 and older, will switch from their current IVIG to V-IMMUNE every three weeks for a year. The study aims to see if V-IMMU…
Phase 3 • Sponsor: On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Scientists launch major study to unravel mysteries of rare immune diseases
Knowledge-focused Recruiting nowThis study aims to understand the causes and progression of Common Variable Immunodeficiency (CVID) and related inborn errors of immunity. Researchers will observe up to 500 patients over time using blood tests, imaging, and other exams. The goal is to find better ways to diagnos…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Fatigue in MS might be caused by low antibodies – new study investigates
Knowledge-focused Recruiting nowThis study looks at whether low levels of immunoglobulin G (IgG), a type of antibody, are linked to fatigue in people with multiple sclerosis (MS). Researchers will compare fatigue scores and infection rates between MS patients with low IgG and those with normal IgG. The goal is …
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Body fat may change how well immune therapy works
Knowledge-focused Recruiting nowThis study looks at how a person's body composition (fat and muscle) affects the way immunoglobulin G (IgG) moves through the body after being given through a vein or under the skin. Researchers will enroll 20 adults with a nerve condition called CIDP who already receive IgG ther…
Phase 1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Could a gene flaw weaken immunity in Alpha-1 patients?
Knowledge-focused Recruiting nowThis study aims to understand why some people with alpha-1 antitrypsin deficiency (AATD) get more respiratory infections. Researchers will compare immune responses to a pneumonia vaccine (PCV20) in 30 adults who carry one abnormal copy of the SERPINA1 gene. Half have had frequent…
Phase 4 • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC